Brief: Medincell Posts H1 Income From Ordinary Activities Of EUR 8.2 Million

Medincell SA

19/12/2023 16:51

Dec 19 (Reuters) - Medincell SA  MEDCL.PA :
    * H1 INCOME FROM ORDINARY ACTIVITIES: EUR 8.2 MILLION (+6.1%
VERSUS. FIRST HALF OF PREVIOUS YEAR, OF WHICH EUR 7.0 MILLION IN
REVENUE, +15.9%)
    * H1 OPERATING EXPENSES: EUR 17.1 MILLION (-11.5% VERSUS.
FIRST
HALF OF PREVIOUS YEAR)
    * H1 NET RESULT: EUR -8.2 MILLION (VERSUS. EUR -13.7 MILLION
IN
FIRST HALF OF PREVIOUS YEAR)
    * END-H1 AVAILABLE CASH: EUR 26.8 MILLION (OF WHICH EUR 15.0
MILLION IN NON-RISKY CURRENT FINANCIAL ASSETS)
    * ACCELERATION OF PHASE 3 CLINICAL TRIAL OF MDC-TJK, SECOND
ANTIPSYCHOTIC DEVELOPED WITH TEVA, WITH RESULTS NOW EXPECTED IN
SECOND HALF OF 2024
    * END OF RECRUITMENT FOR PHASE 3 CLINICAL TRIAL OF MDC-CWM
PROGRAM
(POST-OPERATIVE PAIN), WITH ANALYSIS OF EFFICACY RESULTS
EXPECTED IN Q1 OF 2024
    * PROGRESS IN REST OF PORTFOLIO, WITH CLINICAL TRIALS OF
SEVERAL
PROGRAMS SCHEDULED TO START IN 2024
    * IN BASELINE FORECAST SCENARIO, MEDINCELL IS FULLY ABLE TO
MEET
ITS CONTRACTUAL FINANCIAL COMMITMENTS TO EIB WITHIN NEXT TWELVE
MONTHS IN TERMS OF PROJECTED CASH FLOW

Source text for Eikon:  ID:nBw3hZhHJa 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))